Innovent's third-quarter 2026 revenue grew over 40% year-on-year, exceeding CNY 4.7 billion, driven by mazdutide, its GLP-1 drug, and recent proprietary products such as SINTBILO and SYCUME, two innovative injections.
The GLP-1 market remains underpenetrated at less than 1% in China as of 2025, giving Innovent an advantage in the dual-agonist industry.
Mazdutide competition becomes greater than expected, leading to price wars.
Metric | 01801 | NVO | MRK |
|---|---|---|---|
Price/Earnings (Normalized) | 87.90 | 10.18 | 109.34 |
Price/Book Value | 6.90 | 5.49 | 8.09 |
Price/Sales | 8.83 | 3.52 | 5.41 |
Price/Cash Flow | 60.48 | 9.25 | 16.45 |
Metric | 01801 | NVO | MRK |
|---|---|---|---|
Quick Ratio | 2.48 | 0.63 | 0.78 |
Current Ratio | 2.68 | 0.84 | 1.35 |
Interest Coverage | 17.01 | — | 3.33 |
Metric | 01801 | NVO | MRK |
|---|---|---|---|
Return on Assets (Normalized) | 6.48% | 20.15% | 2.53% |
Return on Equity (Normalized) | 13.49% | 56.25% | 7.02% |
Return on Invested Capital (Normalized) | 8.48% | 33.34% | 4.79% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|z!VP&Rs | LOCK|%<S# | $139B | |||
| Moderna Inc MRNA | LOCK|JP@g?q | LOCK|>#T | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|b&$<^H | LOCK|f%%$ | $99B | |||
| argenx SE ADR ARGX | LOCK|p@>mlY | LOCK|<$ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|fjGKs& | LOCK|qSC | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|rS^V<&# | LOCK|!%&G | $31B | |||
| Incyte Corp INCY | LOCK|&q&g@d | LOCK|$C< | $25B | |||
| BioNTech SE ADR BNTX | LOCK|!ym$h^ | LOCK|>#s | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$m@ctm? | LOCK|?Phk | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|gN@@@N | LOCK|??! | $16B |
United States